A Phase 3 interventional study of CYD Dengue Vaccine and Tdap: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine adsorbed in Dengue Fever and Dengue Hemorrhagic Fever, sponsored by Sanofi Pasteur, a Sanofi Company. Terminated at 4 sites in Philippines. Open to participants aged 9 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-25.
Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Severe Dengue by Sanofi — none open to participants now, none under way, none of them phase 3. Severe Dengue · Sanofi.
Among the 29 studies in Severe Dengue by Sanofi, this one is the 9th largest by enrollment of the 26 interventional ones that give a count, is one of 7 that started in 2016, is one of 9 in phase 3, and was the 28th registered.
65 studies on the registry are indexed under Severe Dengue; 5 are open to participants now.
Browse Severe Dengue studies →None of the 29 studies in Severe Dengue by Sanofi is open now. The open studies under Severe Dengue, anywhere →
Of the 4 Severe Dengue studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; 2 take children under 18; 2 take healthy volunteers.
This study: 9 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 7 started in 2016.
This study's enrollment of 688 is above the median of 170 across 52 interventional studies indexed under Severe Dengue.
Median enrollment 345 across the 26 interventional studies, 3,203 across the 3 observational. Of the 29 that completed or were terminated, 24 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Sanofi Pasteur, a Sanofi Company, one of the names counted as Sanofi. Under that name alone:
Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.
Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 29 studies in Severe Dengue by Sanofi, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of the study was to investigate the immunogenicity and safety of CYD dengue vaccine and Tetanus Toxoid (T), Reduced Diphtheria Toxoid (D) and Acellular Pertussis Vaccine Adsorbed (ap) (Tdap) vaccine when both vaccines were administered concomitantly or sequentially.
Primary Objectives:
Secondary Objectives:
Participants were to receive CYD dengue vaccine according to a 3-dose schedule administered 6 months apart, with the first dose of CYD dengue vaccine administered either concomitantly or sequentially with a booster dose of the Tdap vaccine, Adacel®.
During the conduct of the study, a safety signal was identified which led to the Independent Data Monitoring Committee (IDMC) recommendation not to vaccinate participants who had never been infected by dengue prior to the first injection, i.e., dengue non-immune participants. The protocol was amended accordingly but never implemented due to absence of response of Health Authorities (HA) from The Philippines.
After having waited for more than 1.5 years, and as the participants became out of window to complete their immunization schedule and the last safety follow-up call (6 months after the last dose), the Sponsor decided to stop the trial. Participants only attended a last safety follow-up visit to terminate the study and were informed about the end of the study. As a consequence, the study was prematurely terminated before injection of the last dose (3rd dose) of the CYD dengue vaccine.
As a consequence of the IDMC recommendations, the main immunogenicity analyses were done in dengue immune participants which is not what was planned in the protocol (and this is why the primary endpoints are not exactly the same as those defined in the protocol as they were finally assessed only in dengue immune participants whereas initially it was planned to be assessed regardless of baseline status).
All participants were assessed for immunogenicity and safety. Safety assessments included solicited reactions within 7 or 14 days after each injection, unsolicited adverse events within 28 days after each injection, and serious adverse events during the study period.
65 studies on the registry are indexed under Severe Dengue; 5 are open to participants now.
This study's enrollment of 688 is above the median of 170 across 52 interventional studies indexed under Severe Dengue.
Browse Severe Dengue studies →Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.
Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.
First submitted after Sanofi Pasteur became part of Sanofi.
Compared within Severe Dengue, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dengue. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
OR For participant aged at least 12 years: known (documented or self-reported) receipt of at least 3 previous doses of diphtheria toxoid, tetanus toxoid, and whole cell pertussis-containing (DTwP) vaccines, with the last dose not within the last 5 years prior to enrolment.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be administered the first dose of CYD dengue vaccine concomitantly with a dose of Tdap vaccine.
Biological: CYD Dengue Vaccine · Biological: Tdap: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine adsorbed
Participants will be administered the first dose of CYD dengue vaccine 28 days after a dose of Tdap vaccine.
Biological: CYD Dengue Vaccine · Biological: Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed
0.5 milliliter (mL), Subcutaneous at Month 1, 7 and Month 13, respectively
Also known as: Dengvaxia®
Drug page: AdacelStudies of AdacelAdacel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
0.5 mL, intramuscularly (IM) at Month 1.
Also known as: Adacel®
Drug page: AdacelStudies of AdacelAdacel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
0.5 mL, intramuscularly at Day 0.
Also known as: Adacel®
Geometric Mean Concentrations (GMCs) of Antibodies Against Pertussis Antigens (Pertussis Toxoid, Filamentous Hemagglutinin, Pertactin, and Fimbriae 2+3) 28 Days After Dose of Tdap Vaccine in Previously Dengue Immune Participants
GMCs against each pertussis antigens (pertussis toxoid \[PT\], filamentous hemagglutinin \[FHA\], pertactin \[PRN\], fimbriae types 2 and 3 \[FIM2+3\]) were assessed using an enzyme-linked immunosorbent assay (ELISA) method and were measured in ELISA unit/milliliter (EU/mL). Dengue immune participants at Baseline were defined as participants with titers \>=10 (1/dilution) for at least one serotype with the parental dengue virus strain.
Time frame: 28 days after Tdap vaccination
Percentage of Participants With Seroprotection Against Diphtheria and Tetanus Antigens 28 Days After the Dose of Tdap Vaccine in the Previously Dengue Immune Participants
Seroprotection against diphtheria (Anti-D) and tetanus (Anti-T) antigens was performed by Micrometabolic Inhibition Test - Toxin Neutralization assay (MIT-TNA) and ELISA, respectively. Seroprotection was defined as anti-D and anti-T Ab concentration greater than 0.1 international units (IU)/mL. Dengue immune participants at Baseline were defined as participants with titers \>=10 (1/dilution) for at least one serotype with the parental dengue virus strain.
Time frame: 28 days after Tdap vaccination
Geometric Mean Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype 28 Days After the First Dose of CYD Dengue Vaccination in the Previously Dengue Immune Participants
The GMTs against each of the four parenteral dengue virus serotypes (1, 2, 3 and 4) of CYD dengue vaccine were assessed using the 50% plaque reduction neutralization test (PRNT50) assay method. Dengue immune participants at Baseline were defined as participants with titers \>=10 (1/dilution) for at least one serotype with the parental dengue virus strain. Titers were measured in terms of 1/dilution.
Time frame: 28 days after first CYD dengue vaccination
Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype at Baseline and 28 Days After the First Dose of CYD Dengue Vaccination in the Previously Dengue Immune Participants
The GMTs against each of the four parenteral dengue virus serotypes (1, 2, 3 and 4) of CYD dengue vaccine were assessed using PRNT50 assay method. Dengue immune participants at Baseline were defined as participants with titers \>=10 (1/dilution) for at least one serotype with the parental dengue virus strain. Titers were measured in terms of 1/dilution.
Time frame: Baseline (Pre-CYD vaccination 1) and 28 days after the first CYD dengue vaccination
Percentage of Participants With Neutralizing Antibody Titers Against Each of the 4 Dengue Virus Serotypes of CYD at Baseline and 28 Days After First Dose of CYD Dengue Vaccination in the Previously Dengue Immune Participants
The GMTs against each of the four parenteral dengue virus serotypes (1, 2, 3 and 4) of CYD dengue vaccine were assessed using PRNT50 assay method. Dengue immune participants at Baseline were defined as participants with titers \>=10 (1/dilution) for at least one serotype with the parental dengue virus strain.
Time frame: Baseline (Pre-CYD vaccination 1) and 28 days after the first CYD dengue vaccination
Percentage of Participants With Neutralizing Antibody Titers Above Predefined Thresholds Against at Least 1, 2, 3, or 4 Serotypes of CYD at Baseline and 28 Days After the First Dose of CYD Dengue Vaccination in the Previously Dengue Immune Participants
Dengue neutralizing antibody levels against each of the 4 dengue virus serotypes (1, 2, 3, and 4) were measured by PRNT50. Dengue immune participants at Baseline were defined as participants with titers \>=10 (1/dilution) for at least one serotype with the parental dengue virus strain. Percentage of participants with neutralizing antibody titers above pre-defined thresholds (\>=10 and \>=100 \[1/dilution\]) against at least 1, 2, 3, or 4 serotypes of CYD were reported. Here, 'dil'=dilution and "vac"=vaccination in the specified categories.
Time frame: Baseline (Pre-CYD vaccination 1) and 28 days after the first CYD dengue vaccination
Geometric Mean Concentrations of Serum Antibodies Against Pertussis Antigens (Pertussis Toxoid, Filamentous Hemagglutinin, Pertactin, and Fimbriae 2+3) at Baseline and 28 Days After the Dose of Tdap Vaccine in the Previously Dengue Immune Participants
GMCs against each pertussis antigens (PT, FHA, PRN, FIM2+3) were assessed using ELISA assay method and were measured in EU/mL. Dengue immune participants at Baseline were defined as participants with titers \>=10 (1/dilution) for at least one serotype with the parental dengue virus strain.
Time frame: Baseline (Pre-Tdap vaccination) and 28 days after the Tdap vaccination
Percentage of Participants Achieving Serum Antibody (>=0.1 IU/mL) Against Diphtheria and Tetanus Antigens at Baseline and 28 Days After the Dose of Tdap Vaccine in the Previously Dengue Immune Participants
The GMC against diphtheria and tetanus antigens was performed by MIT-TNA and ELISA, respectively. Dengue immune participants at Baseline were defined as participants with titers \>=10 (1/dilution) for at least one serotype with the parental dengue virus strain.
Time frame: Baseline (Pre-Tdap vaccination) and 28 days after the dose of Tdap vaccination
Number of Participants With Immediate Unsolicited Adverse Events (AE) Following Vaccination With Tdap or CYD Dengue Vaccine
An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the electronic case report form (eCRF) in terms of diagnosis and/or onset post-vaccination. Any unsolicited AE occurred during first 30 minutes post-vaccination was recorded on the CRF as immediate AE. At Visit 1, participants of Group 1 received no vaccination and participants of Group 2 received only Tdap vaccination. At Visit 2, participants of Group 1 received both CYD and Tdap vaccination and participants of Group 2 received only CYD vaccination. At Visit 4, participants of Groups 1 and 2 received CYD vaccination.
Time frame: Within 30 minutes after any and each vaccination
Number of Participants With Solicited Injection Site Reactions Following Vaccination With Tdap or CYD Dengue Vaccine
A solicited reaction (SR) was an AE observed and reported under the conditions (symptom and onset) prelisted (i.e., solicited) in the eCRF and considered as related to vaccination. Solicited injection site reactions included pain, erythema, and swelling. At Visit 1, participants of Group 1 received no vaccination and participants of Group 2 received only Tdap vaccination. At Visit 2, participants of Group 1 received both CYD and Tdap vaccinations and participants of Group 2 received only CYD vaccination. At Visit 4, participants of Groups 1 and 2 received only CYD vaccination.
Time frame: Within 7 days after any and each vaccination
Number of Participants With Solicited Systemic Reactions Following Vaccination With Tdap or CYD Dengue Vaccine
A SR reaction was an AE observed and reported under the conditions (symptom and onset) prelisted (i.e., solicited) in the CRF and considered as related to vaccination. Solicited injection site reactions included fever, headache, malaise, myalgia, and asthenia. At Visit 1, participants of Group 1 received no vaccination and participants of Group 2 received only Tdap vaccination. At Visit 2, participants of Group 1 received both CYD and Tdap vaccinations and participants of Group 2 received only CYD vaccination. At Visit 4, participants of Groups 1 and 2 received only CYD vaccination.
Time frame: Within 14 days after any and each vaccination
Number of Participants Reporting Unsolicited Adverse Events Following Vaccination With Tdap or CYD Dengue Vaccine
An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the eCRF in terms of diagnosis and/or onset post-vaccination. At Visit 1, participants of Group 1 received no vaccination and participants of Group 2 received only Tdap vaccination. At Visit 2, participants of Group 1 received both CYD and Tdap vaccinations and participants of Group 2 received only CYD vaccination. At Visit 4, participants of Groups 1 and 2 received CYD vaccination.
Time frame: Within 28 days after any and each vaccination
Number of Participants Reporting Non-serious Adverse Event of Special Interests (AESIs) Following Vaccination With Tdap or CYD Dengue Vaccine
Non-serious AESIs were non-serious AEs that were considered by the Sponsor to be relevant for the monitoring of the safety profile of the investigational vaccine. At Visit 1, participants of Group 1 received no vaccination and participants of Group 2 received only Tdap vaccination. At Visit 2, participants of Group 1 received both CYD and Tdap vaccinations and participants of Group 2 received only CYD vaccination. At Visit 4, participants of Groups 1 and 2 received CYD vaccination.
Time frame: Within 7 days post any and each vaccination
Number of Participants Reporting Serious Adverse Events (SAEs) and Serious AESIs Following Vaccination With Tdap or CYD Dengue Vaccine
SAEs were AEs resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening; required hospitalization or prolonged existing hospitalization; persistent or significant disability/incapacity; congenital anomaly or a medically important event. Serious AESIs were SAEs that were considered by the Sponsor to be relevant for the monitoring of the safety profile of the investigational vaccine.
Time frame: From Day 0 up to 6 months after the last Tdap or CYD vaccination
Number of Participants Reporting Cases of Virologically Confirmed Dengue (VCD) Hospitalization Following Vaccination With Tdap or CYD Dengue Vaccine
Hospitalized suspected dengue case was defined as an acute febrile illness with diagnosis of dengue requiring hospitalization (with bed attribution). In such cases, 1 unplanned acute blood sample (within the first 5 days after fever onset) was collected for virological confirmation of hospitalized suspected dengue case. A suspected case was considered VCD if there was a detection of wild type dengue virus by dengue non-structural protein 1 antigen ELISA and/or dengue reverse transcriptase-polymerase chain reactions.
Time frame: From Day 0 up to 6 months after the last Tdap or CYD vaccination
Study participants were enrolled from 19 December 2016 to 17 April 2017 at 4 centers in the Philippines. A total of 688 participants were enrolled and randomized in this study.
| Milestone | CYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration) | CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration) |
|---|---|---|
| Started | 346 | 342 |
| Safety analysis set (safas) | 338 | 342 |
| Completed | 0 | 0 |
| Not completed | 346 | 342 |
| Withdrew: Withdrawal by subject | 11 | 12 |
| Withdrew: Non-compliance with the protocol | 308 | 308 |
| Withdrew: Lost to follow-up | 27 | 22 |
GMCs against each pertussis antigens (pertussis toxoid \[PT\], filamentous hemagglutinin \[FHA\], pertactin \[PRN\], fimbriae types 2 and 3 \[FIM2+3\]) were assessed using an enzyme-linked immunosorbent assay (ELISA) method and were measured in ELISA unit/milliliter (EU/mL). Dengue immune participants at Baseline were defined as participants with titers \>=10 (1/dilution) for at least one serotype with the parental dengue virus strain.
| EU/mL | CYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration) | CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration) |
|---|---|---|
| Anti-PT | 65.2 (57.7 to 73.8) | 76.0 (67.9 to 85.1) |
| Anti-FHA | 273 (248 to 299) | 267 (241 to 296) |
| Anti-PRN | 50.6 (41.4 to 61.9) | 44.9 (36.7 to 55.0) |
| Anti-FIM2+3 | 705 (586 to 847) | 643 (537 to 770) |
Seroprotection against diphtheria (Anti-D) and tetanus (Anti-T) antigens was performed by Micrometabolic Inhibition Test - Toxin Neutralization assay (MIT-TNA) and ELISA, respectively. Seroprotection was defined as anti-D and anti-T Ab concentration greater than 0.1 international units (IU)/mL. Dengue immune participants at Baseline were defined as participants with titers \>=10 (1/dilution) for at least one serotype with the parental dengue virus strain.
| percentage of participants | CYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration) | CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration) |
|---|---|---|
| Anti-D | 90.1 (86.2 to 93.1) | 89.8 (85.9 to 92.9) |
| Anti-T | 98.4 (96.3 to 99.5) | 99.0 (97.2 to 99.8) |
The GMTs against each of the four parenteral dengue virus serotypes (1, 2, 3 and 4) of CYD dengue vaccine were assessed using the 50% plaque reduction neutralization test (PRNT50) assay method. Dengue immune participants at Baseline were defined as participants with titers \>=10 (1/dilution) for at least one serotype with the parental dengue virus strain. Titers were measured in terms of 1/dilution.
| titers | CYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration) | CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration) |
|---|---|---|
| Serotype 1 | 513 (427 to 617) | 461 (384 to 552) |
| Serotype 2 | 677 (588 to 780) | 568 (489 to 661) |
| Serotype 3 | 653 (558 to 765) | 706 (603 to 828) |
| Serotype 4 | 378 (324 to 442) | 472 (404 to 551) |
The GMTs against each of the four parenteral dengue virus serotypes (1, 2, 3 and 4) of CYD dengue vaccine were assessed using PRNT50 assay method. Dengue immune participants at Baseline were defined as participants with titers \>=10 (1/dilution) for at least one serotype with the parental dengue virus strain. Titers were measured in terms of 1/dilution.
| titers | CYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration) | CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration) |
|---|---|---|
| Serotype 1: Pre-vaccination 1 | 265 (218 to 322) | 250 (208 to 300) |
| Serotype 1: 28 days post-vaccination 1 | 513 (427 to 616) | 468 (392 to 560) |
| Serotype 2: Pre-vaccination 1 | 404 (350 to 467) | 343 (294 to 401) |
| Serotype 2: 28 days post-vaccination 1 | 679 (589 to 781) | 577 (497 to 671) |
| Serotype 3: Pre-vaccination 1 | 327 (274 to 391) | 327 (280 to 383) |
| Serotype 3: 28 days post-vaccination 1 | 655 (559 to 767) | 709 (605 to 830) |
| Serotype 4: Pre-vaccination 1 | 136 (115 to 160) | 172 (150 to 197) |
| Serotype 4: 28 days post-vaccination 1 | 379 (325 to 443) | 478 (410 to 557) |
The GMTs against each of the four parenteral dengue virus serotypes (1, 2, 3 and 4) of CYD dengue vaccine were assessed using PRNT50 assay method. Dengue immune participants at Baseline were defined as participants with titers \>=10 (1/dilution) for at least one serotype with the parental dengue virus strain.
| percentage of participants | CYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration) | CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration) |
|---|---|---|
| Serotype 1: Pre-vaccination 1 | 92.7 (89.2 to 95.3) | 93.3 (90.0 to 95.8) |
| Serotype 1: 28 days post-vaccination 1 | 97.8 (95.4 to 99.1) | 98.4 (96.3 to 99.5) |
| Serotype 2: Pre-vaccination 1 | 98.1 (95.9 to 99.3) | 96.5 (93.8 to 98.2) |
| Serotype 2: 28 days post-vaccination 1 | 100.0 (98.8 to 100.0) | 99.0 (97.2 to 99.8) |
| Serotype 3: Pre-vaccination 1 | 95.5 (92.6 to 97.5) | 97.1 (94.6 to 98.7) |
| Serotype 3: 28 days post-vaccination 1 | 100.0 (98.8 to 100.0) | 99.7 (98.2 to 100.0) |
| Serotype 4: Pre-vaccination 1 | 93.0 (89.6 to 95.6) | 97.5 (95.1 to 98.9) |
| Serotype 4: 28 days post-vaccination 1 | 99.4 (97.7 to 99.9) | 100.0 (98.8 to 100.0) |
Dengue neutralizing antibody levels against each of the 4 dengue virus serotypes (1, 2, 3, and 4) were measured by PRNT50. Dengue immune participants at Baseline were defined as participants with titers \>=10 (1/dilution) for at least one serotype with the parental dengue virus strain. Percentage of participants with neutralizing antibody titers above pre-defined thresholds (\>=10 and \>=100 \[1/dilution\]) against at least 1, 2, 3, or 4 serotypes of CYD were reported. Here, 'dil'=dilution and "vac"=vaccination in the specified categories.
| percentage of participants | CYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration) | CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration) |
|---|---|---|
| At least 1 Serotype: pre-vac 1: >=10 (1/dil) | 100.0 (98.8 to 100.0) | 100.0 (98.8 to 100.0) |
| At least 1 Serotype: pre-vac1: >=100 (1/dil) | 97.8 (95.5 to 99.1) | 97.1 (94.6 to 98.7) |
| At least 1 Serotype: post-vac 1: >=10 (1/dil) | 100.0 (98.8 to 100.0) | 100.0 (98.8 to 100.0) |
| At least 1 Serotype: post-vac 1: >=100 (1/dil) | 99.7 (98.2 to 100.0) | 99.7 (98.2 to 100.0) |
| At least 2 Serotype: pre-vac 1: >=10 (1/dil) | 96.5 (93.8 to 98.2) | 98.1 (95.9 to 99.3) |
| At least 2 Serotype: pre-vac 1: >=100 (1/dil) | 84.4 (79.9 to 88.2) | 87.0 (82.8 to 90.5) |
| At least 2 Serotype: post-vac 1: >=10 (1/dil) | 100.0 (98.8 to 100.0) | 99.7 (98.2 to 100.0) |
| At least 2 Serotype: post-vac 1: >=100 (1/dil) | 95.8 (93.0 to 97.8) | 96.5 (93.8 to 98.2) |
| At least 3 Serotype: pre-vac 1: >=10 (1/dil) | 93.6 (90.3 to 96.1) | 95.2 (92.3 to 97.3) |
| At least 3 Serotype: pre-vac 1: >=100 (1/dil) | 76.1 (71.0 to 80.7) | 76.8 (71.8 to 81.4) |
| At least 3 Serotype: post-vac 1: >=10 (1/dil) | 99.7 (98.2 to 100.0) | 99.4 (97.7 to 99.9) |
| At least 3 Serotype: post-vac 1: >=100 (1/dil) | 90.4 (86.6 to 93.4) | 92.1 (88.5 to 94.8) |
| At least 4 Serotype: pre-vac 1: >=10 (1/dil) | 89.2 (85.2 to 92.4) | 91.1 (87.4 to 94.0) |
| At least 4 Serotype: pre-vac 1: >=100 (1/dil) | 52.9 (47.2 to 58.5) | 54.3 (48.6 to 59.9) |
| At least 4 Serotype: post-vac 1: >=10 (1/dil) | 97.4 (95.0 to 98.9) | 98.1 (95.9 to 99.3) |
| At least 4 Serotype: post-vac 1: >=100 (1/dil) | 73.8 (68.6 to 78.6) | 75.6 (70.4 to 80.2) |
GMCs against each pertussis antigens (PT, FHA, PRN, FIM2+3) were assessed using ELISA assay method and were measured in EU/mL. Dengue immune participants at Baseline were defined as participants with titers \>=10 (1/dilution) for at least one serotype with the parental dengue virus strain.
| EU/mL | CYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration) | CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration) |
|---|---|---|
| Anti-PT: Pre-vaccination | 8.46 (7.34 to 9.75) | 9.56 (8.33 to 11.0) |
| Anti-PT: 28 days post-vaccination | 65.0 (57.5 to 73.5) | 76.1 (68.1 to 85.2) |
| Anti-FHA: Pre-vaccination | 19.9 (17.6 to 22.6) | 19.4 (17.1 to 22.1) |
| Anti-FHA: 28 days post-vaccination | 272 (248 to 299) | 266 (240 to 295) |
| Anti-PRN: Pre-vaccination | 3.79 (3.39 to 4.24) | 3.65 (3.25 to 4.10) |
| Anti-PRN: 28 days post-vaccination | 50.6 (41.4 to 61.8) | 45.0 (36.8 to 55.1) |
| Anti-FIM2+3: Pre-vaccination | 15.1 (12.4 to 18.5) | 14.9 (12.2 to 18.1) |
| Anti-FIM2+3: 28 days post-vaccination | 700 (583 to 841) | 642 (537 to 769) |
The GMC against diphtheria and tetanus antigens was performed by MIT-TNA and ELISA, respectively. Dengue immune participants at Baseline were defined as participants with titers \>=10 (1/dilution) for at least one serotype with the parental dengue virus strain.
| percentage of participants | CYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration) | CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration) |
|---|---|---|
| Anti-D: Pre-vaccination | 31.8 (26.7 to 37.3) | 32.8 (27.6 to 38.3) |
| Anti-T: Pre-vaccination | 63.7 (58.1 to 69.0) | 69.6 (64.2 to 74.7) |
| Anti-D: 28 days post-vaccination | 90.1 (86.2 to 93.2) | 89.8 (86.0 to 92.9) |
| Anti-T: 28 days post-vaccination | 98.1 (95.8 to 99.3) | 99.0 (97.2 to 99.8) |
An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the electronic case report form (eCRF) in terms of diagnosis and/or onset post-vaccination. Any unsolicited AE occurred during first 30 minutes post-vaccination was recorded on the CRF as immediate AE. At Visit 1, participants of Group 1 received no vaccination and participants of Group 2 received only Tdap vaccination. At Visit 2, participants of Group 1 received both CYD and Tdap vaccination and participants of Group 2 received only CYD vaccination. At Visit 4, participants of Groups 1 and 2 received CYD vaccination.
| Participants | CYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration) | CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration) |
|---|---|---|
| Post any vaccination | 0 | 0 |
| Post Tdap vaccination 1 (Visit 1) | — | 0 |
| Post CYD/Tdap vaccination (Visit 2) | 0 | 0 |
| Post CYD vaccination 2 (Visit 4) | 0 | 0 |
A solicited reaction (SR) was an AE observed and reported under the conditions (symptom and onset) prelisted (i.e., solicited) in the eCRF and considered as related to vaccination. Solicited injection site reactions included pain, erythema, and swelling. At Visit 1, participants of Group 1 received no vaccination and participants of Group 2 received only Tdap vaccination. At Visit 2, participants of Group 1 received both CYD and Tdap vaccinations and participants of Group 2 received only CYD vaccination. At Visit 4, participants of Groups 1 and 2 received only CYD vaccination.
| Participants | CYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration) | CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration) |
|---|---|---|
| Pain: Post any vaccination | 229 | 237 |
| Pain: Post Tdap vaccination (Visit 1) | — | 212 |
| Pain: Post CYD/Tdap vaccination (Visit 2) | 218 | 53 |
| Pain: Post CYD vaccination 2 (Visit 4) | 61 | 55 |
| Erythema: Post any vaccination | 14 | 17 |
| Erythema: Post Tdap vaccination (Visit 1) | — | 14 |
| Erythema: Post CYD/Tdap vaccination (Visit 2) | 13 | 5 |
| Erythema: Post CYD vaccination 2 (Visit 4) | 2 | 2 |
| Swelling: Post any vaccination | 25 | 32 |
| Swelling: Post Tdap vaccination (Visit 1) | — | 30 |
| Swelling: Post CYD/Tdap vaccination (Visit 2) | 25 | 3 |
| Swelling: Post CYD vaccination 2 (Visit 4) | 2 | 2 |
A SR reaction was an AE observed and reported under the conditions (symptom and onset) prelisted (i.e., solicited) in the CRF and considered as related to vaccination. Solicited injection site reactions included fever, headache, malaise, myalgia, and asthenia. At Visit 1, participants of Group 1 received no vaccination and participants of Group 2 received only Tdap vaccination. At Visit 2, participants of Group 1 received both CYD and Tdap vaccinations and participants of Group 2 received only CYD vaccination. At Visit 4, participants of Groups 1 and 2 received only CYD vaccination.
| Participants | CYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration) | CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration) |
|---|---|---|
| Fever: Post any vaccination | 21 | 30 |
| Fever: Post Tdap vaccination (Visit 1) | — | 15 |
| Fever: Post CYD/Tdap vaccination (Visit 2) | 11 | 6 |
| Fever: Post CYD vaccination 2 (Visit 4) | 10 | 9 |
| Headache: Post any vaccination | 89 | 115 |
| Headache: Post Tdap vaccination (Visit 1) | — | 83 |
| Headache: Post CYD/Tdap vaccination (Visit 2) | 70 | 33 |
| Headache: Post CYD vaccination 2 (Visit 4) | 36 | 35 |
| Malaise: Post any vaccination | 91 | 111 |
| Malaise: Post Tdap vaccination (Visit 1) | — | 81 |
| Malaise: Post CYD/Tdap vaccination (Visit 2) | 74 | 28 |
| Malaise: Post CYD vaccination 2 (Visit 4) | 32 | 33 |
| Myalgia: Post any vaccination | 74 | 100 |
| Myalgia: Post Tdap vaccination (Visit 1) | — | 78 |
| Myalgia: Post CYD/Tdap vaccination (Visit 2) | 67 | 30 |
| Myalgia: Post CYD vaccination 2 (Visit 4) | 26 | 22 |
| Asthenia: Post any vaccination | 67 | 94 |
| Asthenia: Post Tdap vaccination (Visit 1) | — | 69 |
| Asthenia: Post CYD/Tdap vaccination (Visit 2) | 59 | 24 |
| Asthenia: Post CYD vaccination 2 (Visit 4) | 19 | 22 |
An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the eCRF in terms of diagnosis and/or onset post-vaccination. At Visit 1, participants of Group 1 received no vaccination and participants of Group 2 received only Tdap vaccination. At Visit 2, participants of Group 1 received both CYD and Tdap vaccinations and participants of Group 2 received only CYD vaccination. At Visit 4, participants of Groups 1 and 2 received CYD vaccination.
| Participants | CYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration) | CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration) |
|---|---|---|
| Post any vaccination | 56 | 70 |
| Post Tdap vaccination (Visit 1) | — | 40 |
| Post CYD/Tdap vaccination (Visit 2) | 37 | 20 |
| Post CYD vaccination 2 (Visit 4) | 28 | 26 |
Non-serious AESIs were non-serious AEs that were considered by the Sponsor to be relevant for the monitoring of the safety profile of the investigational vaccine. At Visit 1, participants of Group 1 received no vaccination and participants of Group 2 received only Tdap vaccination. At Visit 2, participants of Group 1 received both CYD and Tdap vaccinations and participants of Group 2 received only CYD vaccination. At Visit 4, participants of Groups 1 and 2 received CYD vaccination.
| Participants | CYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration) | CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration) |
|---|---|---|
| Post any vaccination | 0 | 0 |
| Post Tdap vaccination (Visit 1) | — | 0 |
| Post CYD/Tdap vaccination (Visit 2) | 0 | 0 |
| Post CYD vaccination 2 (Visit 4) | 0 | 0 |
SAEs were AEs resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening; required hospitalization or prolonged existing hospitalization; persistent or significant disability/incapacity; congenital anomaly or a medically important event. Serious AESIs were SAEs that were considered by the Sponsor to be relevant for the monitoring of the safety profile of the investigational vaccine.
| Participants | CYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration) | CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration) |
|---|---|---|
| SAE | 8 | 11 |
| Serious AESI | 1 | 3 |
Hospitalized suspected dengue case was defined as an acute febrile illness with diagnosis of dengue requiring hospitalization (with bed attribution). In such cases, 1 unplanned acute blood sample (within the first 5 days after fever onset) was collected for virological confirmation of hospitalized suspected dengue case. A suspected case was considered VCD if there was a detection of wild type dengue virus by dengue non-structural protein 1 antigen ELISA and/or dengue reverse transcriptase-polymerase chain reactions.
| Participants | CYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration) | CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration) |
|---|---|---|
| Number of Participants Reporting Cases of Virologically Confirmed Dengue (VCD) Hospitalization Following Vaccination With Tdap or CYD Dengue Vaccine | 0 | 3 |
Collected over AE data were collected from Day 0 up to Day 28 post any vaccination. SR data were collected from Day 0 up to Day 14 post-vaccination. The SAEs were collected throughout the trial, i.e. up to 6 months after last Tdap or CYD vaccination.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration) | 0/338 (0%) | 8/338 (2.4%) | 248/338 (73.4%) |
| CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration) | 0/342 (0%) | 11/342 (3.2%) | 263/342 (76.9%) |
| Event | CYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration) | CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration) |
|---|---|---|
| Dengue FeverInfections and infestations | 1/338 | 3/342 |
| GastritisGastrointestinal disorders | 1/338 | 0/342 |
| AppendicitisInfections and infestations | 1/338 | 0/342 |
| GastroenteritisInfections and infestations | 1/338 | 1/342 |
| Cerebral InfarctionNervous system disorders | 1/338 | 0/342 |
| Abortion CompletePregnancy, puerperium and perinatal conditions | 1/338 | 0/342 |
| NephrolithiasisRenal and urinary disorders | 1/338 | 0/342 |
| Rash GeneralisedSkin and subcutaneous tissue disorders | 1/338 | 0/342 |
| Hypertensive Heart DiseaseCardiac disorders | 0/338 | 1/342 |
| DyspepsiaGastrointestinal disorders | 0/338 | 1/342 |
| Event | CYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration) | CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration) |
|---|---|---|
| Injection Site PainGeneral disorders | 229/338 | 237/342 |
| HeadacheNervous system disorders | 89/338 | 116/342 |
| MalaiseGeneral disorders | 91/338 | 111/342 |
| MyalgiaMusculoskeletal and connective tissue disorders | 74/338 | 100/342 |
| AstheniaGeneral disorders | 67/338 | 94/342 |
| Injection Site SwellingGeneral disorders | 25/338 | 32/342 |
| PyrexiaGeneral disorders | 22/338 | 32/342 |
| Upper Respiratory Tract InfectionInfections and infestations | 17/338 | 17/342 |
Analysis was performed on all randomized participants.
| Age, Continuous(years) | CYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration) | CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration) | Total |
|---|---|---|---|
| Mean | 26.2 ± 16.3 | 27.1 ± 16.7 | 26.6 ± 16.5 |
| Sex: Female, Male(Participants) | CYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration) | CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration) | Total |
|---|---|---|---|
| Female | 187 | 193 | 380 |
| Male | 159 | 149 | 308 |
| Race and Ethnicity Not Collected(Participants) | CYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration) | CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration) | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Dengue Baseline Status(Participants) | CYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration) | CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration) | Total |
|---|---|---|---|
| Dengue immune | 314 | 315 | 629 |
| Dengue non-immune | 32 | 27 | 59 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Dec 2016 to primary completion in Dec 2019, 35 months.
Results were first posted in Aug 2020, 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adacel
Sanofi Pasteur, a Sanofi Company →